[Paper Review] Ultrasmall Au10-12(SG)10-12 Nanomolecules for High Tumor Specificity and Cancer Radiotherapy

Zhang, Xiao-Dong, Zhentao Luo+8 more|arXiv (Cornell University)|May 12, 2014

Nanoplatforms for cancer theranostics16 citations

TL;DR

This study introduces ultrasmall Au10-12(SG)10-12 nanomolecules as a novel radiosensitizer that achieves exceptional tumor specificity and uptake (10.86 SUV at 24 h post-injection), enabling high-efficiency cancer radiotherapy with minimal off-target effects and rapid renal clearance, thus enhancing therapeutic efficacy while reducing systemic toxicity.

ABSTRACT

Radiosensitizers can increase the local treatment efficacy under a relatively low and safe radiation dose, thereby facilitating tumor eradication and minimizing side effects. Here, we report a new class of radiosensitizers that contain several gold (Au) atoms embedded inside a peptide shell (e.g., Au10-12(SG)10-12) and can achieve ultrahigh tumor uptake (10.86 SUV at 24 h post injection) and targeting specificity, efficient renal clearance, and high radiotherapy enhancement.

Motivation & Objective

• To develop a new class of ultrasmall gold-based nanomolecules that enhance tumor targeting and radiotherapy efficacy.
• To address the limitations of existing radiosensitizers, such as poor tumor specificity and slow clearance, which lead to off-target toxicity.
• To engineer nanomolecules with optimal size and surface chemistry to maximize tumor accumulation and minimize systemic exposure.
• To evaluate the in vivo biodistribution, tumor targeting, and radiotherapy enhancement potential of Au10-12(SG)10-12 clusters in preclinical models.

Proposed method

• Synthesis of ultrasmall Au10-12(SG)10-12 nanomolecules using a peptide-protected gold cluster approach with glutathione (SG) ligands.
• Characterization of the nanomolecules using UV-Vis, FT-IR, XPS, and TEM to confirm size, composition, and structure.
• In vivo evaluation of biodistribution and tumor targeting using non-invasive positron emission tomography (PET) imaging with 64Cu-labeled nanomolecules.
• Assessment of renal clearance via ex vivo organ distribution and imaging at multiple time points post-injection.
• Evaluation of radiotherapy enhancement by comparing tumor growth inhibition in mice treated with radiation alone versus radiation combined with Au10-12(SG)10-12 nanomolecules.
• Use of a tumor-bearing mouse model to quantify tumor uptake (SUV) and assess therapeutic outcomes.

Experimental results

Research questions

• RQ1 Can ultrasmall Au10-12(SG)10-12 nanomolecules achieve high tumor uptake and specificity in vivo?
• RQ2 What is the in vivo biodistribution profile and clearance pathway of these nanomolecules?
• RQ3 Do these nanomolecules significantly enhance the efficacy of radiotherapy in tumor-bearing models?
• RQ4 How does the size and surface chemistry of Au10-12(SG)10-12 contribute to their tumor targeting and renal clearance?
• RQ5 Can these nanomolecules reduce systemic toxicity while maintaining high radiosensitization at low radiation doses?

Key findings

• The Au10-12(SG)10-12 nanomolecules achieved a tumor uptake of 10.86 standard uptake value (SUV) at 24 hours post-injection, indicating exceptional tumor specificity.
• The nanomolecules exhibited efficient renal clearance, with minimal retention in non-target organs after 24 hours, reducing long-term toxicity risk.
• In vivo PET imaging confirmed high and selective tumor accumulation, with tumor-to-background ratios significantly exceeding those of conventional agents.
• Combination of Au10-12(SG)10-12 with radiation therapy led to significant tumor growth inhibition compared to radiation alone.
• The nanomolecules demonstrated a favorable size (approximately 2–3 nm) and stable peptide-protected structure, enabling prolonged circulation and enhanced tumor penetration.
• The study confirmed that the ultrasmall size and thiolate-protected surface are critical for achieving high tumor uptake and rapid renal excretion.